Perimeter Announces Preliminary Second Quarter 2026 Financial Results

Losses narrowed and costs fell, but revenue growth remains modest and unproven commercially.

What the company is saying

Perimeter Medical Imaging AI, Inc. positions its Q2 2026 update as evidence of operational and financial progress, highlighting a 31% sequential increase in recurring revenue from its legacy S-Series OCT and a 28% reduction in operating expenses year-over-year. The company emphasizes its $503,000 in quarterly revenue, entirely from recurring sources, and frames the 33% improvement in net loss as a key milestone. Management draws attention to securing a $148,000 INOVAIT Pilot Fund contribution for Claire's infrastructure and the closing of two capital raises totaling C$13,561,150. The narrative stresses commercial momentum by referencing the first two placements of the Claire device and the deployment at Intermountain Health, but omits numerical detail or customer confirmation for these claims. The tone is upbeat and confident, focusing on cost control and incremental commercial progress, while forward-looking statements are included as standard risk disclaimers.

What the data suggests

The financial data shows Q2 2026 revenue of approximately $503,000, up 31% from $385,000 in Q1 2026 but essentially flat against $506,000 in Q1 2025. All revenue is recurring, with no evidence of new product or service sales. Operating expenses dropped to $3.1 million from $4.3 million a year earlier, a 28% reduction, directly contributing to a net loss improvement from $3.9 million ($0.04 per share) to $2.6 million ($0.02 per share), or 33% year-over-year. Cash used in operations for the first half of 2026 was $5.1 million, down 23% from the prior year, and cash on hand at June 30, 2026 stood at $6.4 million. The company completed a C$7,521,150 equity offering and issued C$6,040,000 in convertible debentures, bolstering liquidity. No audited figures are provided, and operational claims about device placements lack supporting numbers or revenue attribution, limiting the evidence for commercial traction.

Analysis

The announcement's tone is positive but largely proportionate to the disclosed results. The company provides concrete, realised financial metrics: revenue, operating expenses, and net loss, all with clear year-over-year improvements. While there are some forward-looking statements, these are mostly boilerplate and do not dominate the narrative. The capital raises are completed and not aspirational, and there is no evidence of large, uncommitted capital outlays paired with long-dated, uncertain returns. Some operational claims (such as device placements and customer deployments) lack numerical detail, but these are not exaggerated or presented as transformative. The data supports a narrative of incremental progress and improved financial discipline, but profitability remains elusive, capping the signal at weak_positive.

Risk flags

• ●Commercialization risk is high, as claims of Claire device placements and U.S. deployment at Intermountain Health are not supported by customer names, revenue figures, or contract values. Without these details, it is unclear whether these represent pilot programs, paid sales, or non-revenue-generating placements.
• ●Sustainability of recurring revenue growth is uncertain, with Q2 2026 revenue essentially unchanged from Q1 2025 despite sequential improvement. This raises questions about the company's ability to expand its customer base or upsell new products.
• ●Liquidity risk persists, with $6.4 million in cash at June 30, 2026 and $5.1 million used in operations over six months. Without a clear path to profitability or substantial revenue growth, further capital raises may be needed within the next twelve months.
• ●Disclosure risk is present, as preliminary results are unaudited and operational claims lack third-party confirmation or detailed breakdowns. This reduces the reliability of the reported progress and makes it difficult to assess the true commercial impact.

Bottom line

Perimeter Medical Imaging AI, Inc. reports improved cost control and a smaller net loss, but revenue remains flat year-over-year and entirely recurring, with no evidence of new commercial traction from its Claire device. The company has strengthened its balance sheet with two capital raises, but cash burn remains high relative to available funds. Operational claims about new device placements and U.S. deployments are not backed by numbers or customer disclosures, limiting their credibility. The financial trajectory is positive on the expense side, but the lack of audited results and granular revenue detail means the commercial story is still unproven. For investors, the most important takeaway is that while cost discipline is improving, the company has yet to demonstrate meaningful revenue growth or commercial adoption of its new technology. Audited financials and quantified evidence of new sales would be required to materially change this assessment.

Announcement summary

(TSXV:PINK) (OTCQX:PYNKF) Perimeter Medical Imaging AI, Inc. reported preliminary financial results for its second quarter ended June 30, 2026, with revenue of approximately $503,000, all from recurring revenue sources. Recurring revenue from its legacy S-Series OCT grew 31% sequentially quarter-over-quarter. In June 2026, Perimeter was selected to receive a $148,000 contribution from the INOVAIT Pilot Fund to help build the next layer of Claire's infrastructure. In May 2026, Perimeter closed the final tranche of its previously announced 'best efforts' offering, bringing the total offering up to the maximum offering size of 21,489,000 units at a price of $0.35 per unit (C$7,521,150). In June 2026, the Company closed the final tranche of its previously announced non-brokered private placement of C$1,000 principal amount 3.59% convertible debentures, issuing an aggregate of C$6,040,000 principal amount of Convertible Debentures. Operating expenses for the three months ended June 30, 2026 were approximately $3.1 million, down 28% from $4.3 million in the same period in 2025. Second quarter 2026 net loss was approximately $2.6 million, or $0.02 per common share, a 33% improvement compared to approximately $3.9 million, or $0.04 per common share, in the three months ended June 30, 2025.

Disagree with this article?